TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
a Virtual Event
April 10 - 11, 2025
Join us for EHE 360 Connect on Monday, February 24, 2025, 12:00-1:00 pm ET. This webinar features Dr. Scott M. Schuetze, University of Michigan, Rogel Cancer Center, presenting "Results of a Phase 2 Trial of Trametinib in Advanced EHE."
EMPOWER YOURSELF WITH KNOWLEDGE
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
Highlights from CTOS 2024
In November, Denise Robinson, Executive Director and Director of Research attended the CTOS 2024 Annual Meeting in San Diego, CA. The Connective Tissue Oncology Society (CTOS), is a professional medical organization that brings together multi-disciplinary clinician-scientists, translational researchers, and advocates from all over the world to advance the treatment of sarcomas. Many of the world’s […]
Read More
The Pledge: Edition 38, Q3 – July-September, 2024
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe. provide content including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of our online EHE newsletter, The Pledge.
Read More
The EHE Foundation Announces Grant Funding of $307,400 to Advance Research and Find Treatments for EHE
We are pleased to announce The EHE Foundation’s 2024 Research Grants Program awards, totaling $307,400, as part of our ongoing commitment to advance our mission to find effective treatments and a cure for EHE. Made possible by 2023 Giving Tuesday gifts, these grants support novel translational research projects that aim to identify and accelerate the […]
Read More
Making a Donation vs. Fundraising for The EHE Foundation: What’s the Difference?
At The EHE Foundation, we are committed to finding a cure for epithelioid hemangioendothelioma (EHE), an ultra-rare and potentially aggressive cancer that affects one in a million people. Every contribution helps us advance groundbreaking research, support patients, and foster collaboration among clinicians and researchers worldwide. There are two impactful ways you can support our mission: […]
Read More
Scientific & Medical Advisory Board Collaborates to Improve Outcomes for People Living with EHE
On September 10, 2024, The EHE Foundation held a virtual meeting of our Scientific & Medical Advisory Board (SMAB). The meeting aimed to welcome new members, review current research projects, and discuss future needs and goals to advance EHE research. The meeting began with a warm welcome to new members of the SMAB: Tom Chen, […]
Read More
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and is Down-regulated by Sirolimus Through ATF4/ATF5 Suppression
Drs. Silvia Stacchiotti, Sandro Pasquali, and Nadia Zaffaroni (IRCCS – INT, Milan, Italy) and colleagues published their promising findings in Clinical Cancer Research, September 16, 2024. This study, funded in part by The EHE Foundation in partnership with EHE Rare Cancer Charity (UK), aimed to assess the efficacy of sirolimus for the treatment of EHE […]
Read More
Funded Research Project Update: Use of pre-clinical EHE models to identify druggable pathways to treat EHE
Investigator: John Lamar, PhD, Albany Medical College Dr. Lamar was awarded a 3-year grant by The EHE Foundation in 2022, that aims to identify FDA-approved drugs that inhibit EHE cell growth, and then test them in pre-clinical mouse models for the treatment of EHE. What does this mean for patients? This could mean a shorter […]
Read More
Funded Research Project Update: Repurposing an FDA-approved Drug for EHE Treatment
Investigator: Ajaybabu Pobbati, PhD, Cleveland Clinic – Lerner Research Institute In 2022, The EHE Foundation funded a grant to Dr. Pobbati for research that looks at a library of current FDA-approved drugs that act as TAZ-CAMTA1 (TC) or TEAD inhibitors, for use in EHE. What does this mean for patients? This could mean a shorter […]
Read More
Championing Our Cause: How Patients Support Fundraising
Join us for EHE Community Connections as we discuss “Championing Our Cause: How Patients Support Fundraising.” Collaborate with other patients and caregivers to explore the most creative and effective fundraising ideas. Together, let’s talk about how to better engage our own community of donors, create awareness and raise money for this one-in-a-million cancer! This workshop […]
Read More